最新研究：减重药或能减少肥胖者的“食物噪音”

Group 1 - The INFORM study presented at the EASD 2025 conference indicates that the use of the weight management version of semaglutide significantly reduces "food noise" among participants, leading to improvements in mental health and lifestyle [1] - The proportion of patients troubled by "food noise" decreased by 46% during treatment, with 60% reporting negative impacts before treatment, dropping to 20% during treatment [1] - 64% of respondents reported improvements in mental health, with 76% adopting healthier lifestyles and 80% developing better habits; 83% expressed satisfaction with the treatment outcomes [1] Group 2 - The STEP UP trial subgroup analysis shows that patients receiving semaglutide (7.2mg) experienced significant reductions in food cravings, emotional eating, and loss of control over eating compared to the placebo group [2] - The trial demonstrated an average weight reduction of 21% for participants on the higher dose of semaglutide, with one-third achieving a weight loss of 25% or more [2] - The analysis indicates that the weight loss achieved with semaglutide (7.2mg) primarily consists of fat loss (84.5%), which is beneficial for improving body composition and maintaining physical function in overweight or obese patients [2]